BACKGROUND & AIMS: The recruitment of lymphocytes to tissues via endothelium has been studied extensively but less is known about the signals that direct migration and positioning within tissues. Liver myofibroblasts associate with lymphocytes in hepatitis and are positioned below the sinusoidal endothelium, through which lymphocytes are recruited to the liver. We investigated whether activated human liver myofibroblasts (aLMF) affect the migration and accumulation of lymphocytes within the inflamed liver. METHODS: The ability of human aLMF and hepatic stellate cells to promote lymphocyte chemotaxis, adhesion, and migration was studied in vitro. RESULTS: When cultured in vitro, aLMF from diseased human liver and hepatic stellate cells from noninflamed liver secrete a distinct profile of cytokines comprising interleukin (IL)-6, IL-12, hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and the chemokines CCL2, CCL3, CCL5, CXCL8, CXCL9, and CXCL10. aLMF-conditioned media had chemotactic activity for lymphocytes, which partially was inhibited by pertussis toxin. IL-6, HGF, and VEGF all contributed to G-protein-coupled receptor-independent chemotaxis of lymphocytes. Lymphocytes adhered to aLMF via intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 and a proportion of adherent cells migrated through the fibroblast monolayer, mediated by IL-6, HGF, and VEGF. CONCLUSIONS: Human aLMF support G-protein coupled receptor-dependent and -independent lymphocyte adhesion and migration and thereby regulate the recruitment and positioning of lymphocytes in chronic hepatitis.
BACKGROUND & AIMS: The recruitment of lymphocytes to tissues via endothelium has been studied extensively but less is known about the signals that direct migration and positioning within tissues. Liver myofibroblasts associate with lymphocytes in hepatitis and are positioned below the sinusoidal endothelium, through which lymphocytes are recruited to the liver. We investigated whether activated human liver myofibroblasts (aLMF) affect the migration and accumulation of lymphocytes within the inflamed liver. METHODS: The ability of human aLMF and hepatic stellate cells to promote lymphocyte chemotaxis, adhesion, and migration was studied in vitro. RESULTS: When cultured in vitro, aLMF from diseased human liver and hepatic stellate cells from noninflamed liver secrete a distinct profile of cytokines comprising interleukin (IL)-6, IL-12, hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and the chemokines CCL2, CCL3, CCL5, CXCL8, CXCL9, and CXCL10. aLMF-conditioned media had chemotactic activity for lymphocytes, which partially was inhibited by pertussis toxin. IL-6, HGF, and VEGF all contributed to G-protein-coupled receptor-independent chemotaxis of lymphocytes. Lymphocytes adhered to aLMF via intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 and a proportion of adherent cells migrated through the fibroblast monolayer, mediated by IL-6, HGF, and VEGF. CONCLUSIONS:Human aLMF support G-protein coupled receptor-dependent and -independent lymphocyte adhesion and migration and thereby regulate the recruitment and positioning of lymphocytes in chronic hepatitis.
Authors: Stephanie M Martinez; Blair U Bradford; Valerie Y Soldatow; Oksana Kosyk; Amelia Sandot; Rafal Witek; Robert Kaiser; Todd Stewart; Kirsten Amaral; Kimberly Freeman; Chris Black; Edward L LeCluyse; Stephen S Ferguson; Ivan Rusyn Journal: Toxicol Appl Pharmacol Date: 2010-09-24 Impact factor: 4.219
Authors: Marie-Luise Berres; Rory R Koenen; Anna Rueland; Mirko Moreno Zaldivar; Daniel Heinrichs; Hacer Sahin; Petra Schmitz; Konrad L Streetz; Thomas Berg; Nikolaus Gassler; Ralf Weiskirchen; Amanda Proudfoot; Christian Weber; Christian Trautwein; Hermann E Wasmuth Journal: J Clin Invest Date: 2010-10-18 Impact factor: 14.808
Authors: Bertus Eksteen; J Rodrigo Mora; Emma L Haughton; Neil C Henderson; Laura Lee-Turner; Eduardo J Villablanca; Stuart M Curbishley; Alex I Aspinall; Ulrich H von Andrian; David H Adams Journal: Gastroenterology Date: 2009-02-21 Impact factor: 22.682
Authors: P Manousou; G Kolios; I Drygiannakis; M Koulentaki; K Pyrovolaki; A Voumvouraki; G Notas; L Bourikas; H A Papadaki; E Kouroumalis Journal: Clin Exp Immunol Date: 2013-04 Impact factor: 4.330